Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Endocrinology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Endocrinology Other
    Insulin Resistance Increases Risk of Pregnancy, Birth Complications: Presented at ENDO 08 - (DGDispatch)
    Testosterone Gel Improves Insulin Sensitivity, Sexual Function in Hypogonadal Men With Diabetes and Metabolic Syndrome: Presented at ENDO 08 - (DGDispatch)
    Cinacalcet Proves Ineffective for Primary Hyperparathyroidism, Accelerates Bone Loss Over Time: Presented at ENDO 08 - (DGDispatch)
    Metformin Improves Metabolic Syndrome in Obese Children With Insulin Resistance: Presented at ENDO 08 - (DGDispatch)
    Metformin Slows Early-Onset Puberty in Girls - (DGNews)

    News archive

     Recent webcasts/CME - Endocrinology Other
  • Background: Case Studies on Management of Pancreatic Cancer: Current Challenges and Latest Evidence
  • Female Sexual Desire and Aging

    Webcasts/CME archive

     Recent cases - Endocrinology Other
      Pituitary Hypoplasia and Growth Hormone Deficiency in a Woman with Glycogen Storage Disease Type Ia: A Case Report
      Incidental Pheochromocytoma Presenting with Sublaboratory Findings in Asymptomatic Surrenal Masses: A Case Report
      Rapid Intraoperative Insulin Assay: A Novel Method to Differentiate Insulinoma from Nesidioblastosis in the Pediatric Patient
      Primary Aldosteronism Caused by a Unilateral Adrenal Adenoma Accompanied by Autonomous Cortisol Secretion
      Possibly Simultaneous Primary Aldosteronism and Preclinical Cushing's Syndrome in a Patient with Double Adenomas of Right Adrenal Gland

      Cases archive
        




      my personal edition > endocrinology other > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Several Options Available for Androgen Replacement Therapy: Presented at ACP

      By Daniel Keller

      SAN DIEGO, CA -- April 8, 2003 -- Androgen replacement therapy can improve the lives of men who are clinically hypogonadal. By restoring them to a eugonadal state, it can increase muscle mass and strength, help maintain bone density, increase cognition and mood, improve libido and sexual function, and lead to a generalized state of well-being.

      Speaking here at the Annual Session of the American College of Physicians on April 5th, Jacob Rajfer, MD, a professor of urology, Harbor-University of California at Los Angeles Medical Center, in Torrance, California, said that no data have proven that exogenous androgen promotes cardiovascular disease (CVD).

      "So the fear of exacerbating cardiovascular disease should not be an issue," he said. The relative risks and benefits of testosterone on CVD will remain an open question until its effects on specific cardiovascular end points are evaluated in clinical trials.

      Studies suggest that bringing a hypogonadal man back to a normal level of testosterone with exogenous androgen does not affect the prostate negatively. "There is essentially no significant change in the PSA [prostate specific antigen], in prostate volume, and in urinary symptoms," according to Dr. Rajfer.

      For these men, he recommends measuring the PSA level at baseline and 6 weeks after starting therapy. If PSA levels move into the abnormal range, an ultrasound and a biopsy of the prostate gland should be obtained with patient consent, he said. PSA should be monitored every 6 months thereafter. Similarly, hematocrit and liver function tests should be performed every 6 months.

      Androgen preparations consist of oral, parenteral, transdermal patches, and topical gels. Dr. Rajfer strongly recommended against using the oral medications now available in the United States because of hepatotoxicity as well as because of low drug levels from first-pass inactivation through the liver. He said a form of testosterone lacking the methyl group that leads to hepatotoxicity is available in Europe but not in the United States.

      Injectable preparations cause wide swings in testosterone levels, and sometimes patients cannot tolerate the accompanying mood changes. These preparations are, however, the most cost effective, Dr. Rajfer said. Patches provide more constant doses, but many patients complain of dermatologic side effects.

      A currently available testosterone gel is AndroGel®, applied once daily to the shoulder or upper arms, resulting in a steady state testosterone level. Dosing should be titrated according to serum testosterone levels as well as PSA and hematocrit levels.

      Side effects of exogenous androgen therapies are mood changes, polycythemia, gynecomastia, exacerbation of sleep apnea, and in some patients, acne. Most symptomatic hypogonadal men can find a tolerable medication and will benefit from it, Dr. Rajfer said.

      "So [testosterone] treatment in aged men is here to stay," Dr. Rajfer concluded. "The data proves that it enhances their mood, prevents fractures… [and] improves strength, muscle mass, and cognition."



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send